medigraphic.com

2019, Número 3

<< Anterior Siguiente >>

Rev Hematol Mex 2019; 20 (3)


Guía de tratamiento de la leucemia linfocítica crónica/linfoma de linfocitos pequeños

Alvarado-Ibarra M, Mena-Zepeda V, Nava-Villegas L, Estrada-Domínguez P, Alcivar-Cedeño LM, Martínez-Ríos A, Hernández-Ruiz E, Martínez-Ramírez MA, Morales-Adrián J, Álvarez-Vera JL, Salazar-Ramírez O, Arteaga-Ortiz L, Reyes-Brena GN, Loera-Fragozo SJ, de la Peña-Celaya JA, Rojas-Castillejos F, Tepepa-Flores F, Scherling-Ocampo AA, Orellana-Garibay JJ, Tapia-Enríquez AL, Pérez-Zúñiga JM, Jacobo-Medrano E, Herrera-Olivares W, Paredes-Lozano EP, Saavedra-González A, Trejo JE, Espitia-Ríos ME, Silva-Vera K, Arana-Luna EL

Idioma: Español
Referencias bibliográficas: 51
Paginas: 210-223
Archivo PDF: 346.98 Kb.


RESUMEN

Se comunica una guía de diagnóstico y tratamiento de la leucemia linfocítica crónica elaborada por un grupo de expertos mexicanos, con el fin de adaptar los avances obtenidos en los últimos años a la realidad de la población de México. Es una guía orientada no solo a los especialistas, sino también útil para todos los profesionales de la salud implicados en el manejo y cuidado de los pacientes afectados por esta enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cano CR, Alvarado IM, Álvarez PE, Baltazar AS, Castellanos GJE, Castillo RMH y col. Primer consenso en leucemia linfocítica crónica de la Agrupación Mexicana para el Estudio de la Hematología: epidemiología, diagnóstico y tratamiento Med Univer 2008;10(40).

  2. Labardini JR, Cervera E, Corrales C, Balbuena M, Barbosa AA, Espinoza JR y col. Oncoguía. Leucemia Linfocítica Cró- nica. Cancerología 2011;6:117-120. Disponible en http:// incan-mexico.org/revistainvestiga/elementos/documentosPortada/ 1327325816.pdf último acceso Junio-2018

  3. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol 2017 Sep;92(9):946-965.

  4. García-Marco JA, Delgado J, Hernández-Rivas JA, Ramírez Payer Á, Loscertales Pueyo J, Jarque I, et al; en nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC). Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. Med Clin (Barc) 2017 Apr 21;148(8):381.e1-381.e9.

  5. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v78-84.

  6. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016 May 19;127(20):2391-405.

  7. Alvarado M, Mena-Zepeda V, Ortiz-Zepeda M, Álvares- Vera J, et al. Long-term outcomes in patients with chronic lymphocytic leukemia treated with standard therapy. J Leuk 2018;6:1.

  8. Santoyo-Sánchez A, Ramos-Peñafiel CO, Saavedra-González A, González-Almanza E, Martínez-Tovar A, Olarte-Carrillo I. Frecuencias de edad y género de pacientes con leucemia en dos centros de referencia del Valle de México. Gac Méd Méx 2017;153:44-8.

  9. Arena GD, Musto P. Monoclonal B-cell lymphocytosis. Translational Medicine 2014;8(9):75-79.

  10. Zhgang S, Kipps TJ. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol 2014;9:103-18.

  11. Benchimol S. p53-dependent pathways of apoptosis. Cell Death Differ 2001 Nov;8(11):1049-51.

  12. Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer 2016 Mar;16(3):145-62.

  13. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood 2018 Mar 14. pii: blood-2017-09-806398.

  14. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. J Natl Compr Canc Netw 2017 Mar;15(3):293-311.

  15. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998 Feb;25(1):80-97.

  16. Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA 2014 Dec 3;312(21):2265-76.

  17. Tsai CF, Hsu YW, Chen WK, Ho YC, Lu FJ. Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells due to electrolyzed-reduced water and glutathione. Biosci Biotechnol Biochem 2009 Feb;73(2):280-7.

  18. Kersting S, Neppelenbroek SIM, Visser HPJ, van Gelder M, Levin MD, Mous R, et al. Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. Clin Lymphoma Myeloma Leuk 2018 Jan;18(1):52-57.

  19. The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016;17(6):779-790.

  20. Kedar V. Inamdar, pathology of chronic lymphocytic leukemia: an update. Ann Diagnostic Pathology 2007;11:378.

  21. Hernández-Ramírez P. Leucemia linfoide crónica. Diagnóstico y factores pronósticos. Rev Cubana Hematol Inmunol Hemoter 2003 Mayo-dic;19(2-3).

  22. Dearden C. How I treat prolymphocytic leukemia. Blood 2012 Jul 19;120(3):538-51.

  23. Matutes E, Catovsky D. The value of scoring systems for the diagnosis of biphenotypic leukemia and mature B-cell disorders. Leukemia & Lymphoma 1994;13:11-14.

  24. Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol 2007 Jan;136(1):63-72. Epub 2006 Nov 3.

  25. Duma N, Paludo J, Kabat B, Tande A, Chaffee KG, Call TG, et al. Invasive aspergillosis in chronic lymphocytic leukemia: Therapy and outcomes. Blood 2017;130(Suppl 1):4327.

  26. Strati P, Jain N, O’Brien S, et al. Chronic lymphocytic leukemia: Diagnosis and treatment. Mayo Clin Proc 2018 May;93(5):651-64.

  27. Cheson BD, Heitner Enschede S, Cerri E, Desai M, Potluri J, Lamanna N, et al. Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist 2017 Nov;22(11):1283-1291.

  28. Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, et al. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica 2015 Sep;100(9):1180-8.

  29. Voorhies BN, Stephens DM. What is optimal front-line therapy for chronic lymphocytic leukemia in 2017? Curr Treat Options Oncol 2017 Feb;18(2):12.

  30. Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real-world experience. Blood 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

  31. Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, et al. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update. Leuk Lymphoma 2016;57(4):766-82.

  32. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:26, 3559-3566.

  33. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. The international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016 Jul;17(7):928-942.

  34. Deeks ED. Ibrutinib: A review in chronic lymphocytic leukaemia. Drugs 2017 Feb;77(2):225-236.

  35. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015 Dec 17;373(25):2425-37.

  36. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014 Jul 17;371(3):213-23.

  37. Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 2016 Feb;17(2):200-211.

  38. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2014;370:997-1007.

  39. Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol 2017 Mar;4(3):e114-e126.

  40. Ficha Técnica Venetoclax. Disponible en https:// ec.europa.eu/health/documents/community-register/ 2016/20161205136381/anx_136381_es.pdf Último acceso, Mayo-18

  41. Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood 2018 Apr 12;131(15):1704-1711.

  42. Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018 Jan;19(1):65-75.

  43. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018 Mar 22;378(12):1107-1120.

  44. Said R, Tsimberidou AM. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opin Biol Ther 2017 Nov;17(11):1463-1470.Expert Opinion on Biological Therapy

  45. Leblond V, Aktan M,Ferra Coll C.M., Dartigeas C, Kisro J, Montillo M, et al. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study. Haematologica. 2018 Jul 5. pii: haematol.2017

  46. Monserrat E. Leucemia linfocítica crónica: Presente y futuro. Haematologica 2001;86 supl.1:79-85.

  47. Boddu P, Ferrajoli A. Prognostic factors in the era of targeted therapies in CLL. Curr Hematol Malig Rep 2018 Apr;13(2):78-90.

  48. NCCN Clinical Practice Guidelines. Chronic Lymphocytic Leukemia/Small Lynphocytic Lymphoma. Version 5.2018-March 26, 2018.

  49. García Vela JA, García Marco JA. Minimal residual disease in chronic lymphocytic leukaemia. Med Clin 2018;150:144-9.

  50. Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom 2018 Jan;94(1):121-128.

  51. Dutch/Belgium HOVON CLL working group. S.Kersting Dutch guidelines for the diagnosis and treatment of chronic lymphocytic leukaemia. Neth J Med 2016 Feb;74(2):68-74.




2020     |     www.medigraphic.com